LUXLung3-6_2B | R Documentation |
Kaplan-Meier digitized data from LUXLung3-6, figure 2B (PMID 25589191). A reported sample size of 345,364 for a primary endpoint of PFS in lung cancer.
`LUXLung3-6_2B`
A data frame of 364 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (afatinib, gemicitabine-cisplatin) | |
Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–51.
summary(`LUXLung3-6_2B`)
kmplot(`LUXLung3-6_2B`)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.